Held26 days
Entry$44.60Close$50.99PnL+14.33%
65%
confidence
Angle A full round trip to 2022 support leaves BSX priced far below sell-side targets as buyback support absorbs the flush.
BSX has been punished like a broken compounder despite an active buyback, with the accelerated repurchase at $52.68 now far above spot and highlighting the severity of the capitulation [#2]. The reversal case is sentiment and positioning: shares have round-tripped to 2022 levels near a historic support trendline, while referenced upside to average analyst targets remains unusually wide [#4, #5].
AI Status: BSX closed with a +14.33% realized gain after a 26-day rebound from 2022 support, finishing just 0.45% below peak.
The Boston Scientific position realized +14.33% over 26 trading days, peaking at +14.84% maximum favorable excursion with a -5.18% maximum drawdown from entry. Our exit signal closed the trade as daily RSI sat at 69.9 in overbought territory and stochastics pressed the upper band after price reached the 96th percentile of its 20-day range. The capitulation-to-mean-reversion thesis played out before the trade ran its course.
Tweet citations
